Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance

MLA

Justina Januskiene, et al. “Geographical Variation in Reporting Interstitial Lung Disease as an Adverse Drug Reaction: Findings from an European Medicines Agency Analysis of Reports in EudraVigilance.” Pharmacoepidemiology and Drug Safety, vol. 25, Mar. 2016, pp. 705–12. EBSCOhost, https://doi.org/10.1002/pds.3998.

APA

Justina Januskiene, Peter Arlett, Luis Pinheiro, Kevin Blake, & Qun-Ying Yue. (2016). Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance. Pharmacoepidemiology and Drug Safety, 25, 705–712. https://doi.org/10.1002/pds.3998

Chicago

Justina Januskiene, Peter Arlett, Luis Pinheiro, Kevin Blake, and Qun-Ying Yue. 2016. “Geographical Variation in Reporting Interstitial Lung Disease as an Adverse Drug Reaction: Findings from an European Medicines Agency Analysis of Reports in EudraVigilance.” Pharmacoepidemiology and Drug Safety 25 (March): 705–12. doi:10.1002/pds.3998.